There is a significant need for improved treatment options in Progressive Pulmonary Diseases like bronchiectasis and Malabsorption Syndromes such as exocrine pancreatic insufficiency (EPI). While these conditions affect a variety of rare diseases, people living with cystic fibrosis (CF), unfortunately, experience both.
Synspira Therapeutics is a clinical-stage biopharmaceutical company dedicated to significantly improving the lives of people with rare diseases. While we are initially focused in CF, our novel compounds in development are designed to have broad utility across a range of indications within Progressive Pulmonary Disease and Malabsorption Syndromes.
We are committed to developing a rationally designed disease-focused platform to provide novel therapies that overcome the limitations of existing treatments, improve outcomes, reduce patient burden, and can easily become part of patient lives.